Find Clinical Trial

An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)


← Back
Study Phase Phase 3
Therapeutic Area Oncology
Active Substance TIPIRACILTRIFLURIDINETRIFLURIDINE - TIPIRACIL
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS095005
Protocol CodeCL3-95005-006
EudraCT Code2017-004059-22


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.